Experimental drug aims to cut dangerous steroid doses for rare hormone disorder

NCT ID NCT04544410

Terminated Disease control Sponsor: Spruce Biosciences Source: ClinicalTrials.gov ↗

Summary

This study tested whether a drug called Tildacerfont could safely reduce the high doses of steroid medications that adults with classic congenital adrenal hyperplasia (CAH) need to take. About 100 participants were randomly assigned to receive either the study drug or a placebo for 24 weeks, followed by an optional longer-term extension. The main goal was to see if patients could lower their steroid doses to healthier levels while still controlling their hormone imbalance.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Spruce Biosciences Clinical Site

Ann Arbor, Michigan, 48109, United States
Spruce Study Site

Birmingham, Alabama, 35294, United States
Spruce Study Site

Los Angeles, California, 90027, United States
Spruce Study Site

San Diego, California, 92123, United States
Spruce Study Site

Indianapolis, Indiana, 46202, United States
Spruce Study Site

Baltimore, Maryland, 21287, United States
Spruce Study Site

Minneapolis, Minnesota, 55454, United States
Spruce Study Site

New Brunswick, New Jersey, 08901, United States
Spruce Study Site

Canton, Ohio, 44718, United States
Spruce Study Site

Cincinnati, Ohio, 45219, United States
Spruce Study Site

Cleveland, Ohio, 44195, United States
Spruce Study Site

Columbus, Ohio, 43210, United States
Spruce Study Site

Philadelphia, Pennsylvania, 19104, United States
Spruce Study Site

Philadelphia, Pennsylvania, 19107, United States
Spruce Study Site

Philadelphia, Pennsylvania, 19140, United States
Spruce Study Site

Providence, Rhode Island, 02903, United States
Spruce Study Site

Columbia, South Carolina, 29203, United States
Spruce Study Site

Fort Worth, Texas, 76104, United States
Spruce Study Site

Blacktown, Australia
Spruce Study Site

Brisbane, 4029, Australia
Spruce Study Site

Elizabeth Vale, Australia
Spruce Study Site

Parkville, Australia
Spruce Study Site

Curitiba, Brazil
Spruce Study Site

São Paulo, Brazil
Spruce Study Site

Ottawa, Ontario, Canada
Spruce Study Site

Sherbrooke, Quebec, J1H 5N4, Canada
Spruce Study Site

Tallinn, Estonia
Spruce Study Site

Tartu, Estonia
Spruce Study Site

Munich, Germany
Spruce Study Site

Roma, Italy
Spruce Study Site

Riga, Latvia
Spruce Study Site

Kaunas, Lithuania
Spruce Study Site

Krakow, Poland
Spruce Study Site

Warsaw, Poland
Spruce Study Site

Bucharest, Romania
Spruce Study Site

Seoul, South Korea
Spruce Study Site

Barcelona, Spain
Spruce Study Site

Madrid, Spain
Spruce Study Site

Seville, Spain
Spruce Study Site

Tarragona, Spain
Spruce Study Site

Stockholm, Sweden
Spruce Study Site

Istanbul, Turkey (Türkiye)
Spruce Study Site

Birmingham, B15 2GW, United Kingdom

Conditions

Explore the condition pages connected to this study.

CONGENITAL ADRENAL HYPERPLASIA